{"id":9013,"date":"2025-10-23T18:07:00","date_gmt":"2025-10-23T15:07:00","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9013"},"modified":"2025-10-23T18:07:00","modified_gmt":"2025-10-23T15:07:00","slug":"vaccines-for-the-heart-how-preventing-infections-protects-against-heart-attacks-and-stroke","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/vaccines-for-the-heart-how-preventing-infections-protects-against-heart-attacks-and-stroke\/","title":{"rendered":"Vaccines for the Heart \u2014 How Preventing Infections Protects Against Heart Attacks and Stroke"},"content":{"rendered":"
Vaccines for the Heart \u2014 How Preventing Infections Protects Against Heart Attacks and Stroke<\/div>\n
<\/div>\n
Source:<\/div>\n
From discussions and Zoom inputs during the Heart Failure & Prevention, Public Health and National Campaigns, and Heart Transplant & Advanced Heart Failure Roundtable sessions \u2014 First Regional Arab Protocols Conference (Amman, Oct 16\u201317, 2025, based on AHA -ESC preventive protocols<\/div>\n
Keynotes:<\/div>\n
<\/div>\n
1. Acute infections increase risk of cardiovascular (CV) events, and patients with heart disease are more vulnerable to such infections.<\/span><\/div>\n
2. Infection \u2192 systemic inflammation (cytokine surge, oxidative\/immune activation, endothelial dysfunction) \u2192 supports atherogenesis and plaque vulnerability.<\/span><\/div>\n
3. Infection \u2192 hypercoagulability (\u2191 fibrinogen, thrombin activity, platelet binding) \u2192 increased thrombosis risk, triggering acute coronary events.<\/span><\/div>\n
4. Physiologic stress during infection (fever\/hypoxia\/\u2191 metabolic demand\/hypotension\/sympathetic activation) \u2192 demand ischemia or arrhythmia \u2192 Type-2 MI, atrial fibrillation etc.<\/span><\/div>\n
5. Some pathogens directly damage the myocardium (viral myocarditis) \u2192 heart failure or sudden death.<\/span><\/div>\n
6. Epidemiological evidence: e.g., laboratory-confirmed influenza markedly increases risk of acute myocardial infarction in the first week (incidence ratio ~6.05).<\/span><\/div>\n
7. There is a bidirectional relationship: existing CVD \u2191 risk of severe infection, and infection \u2191 risk of CV events \u2192 vaccination as a cardioprotective strategy.<\/span><\/div>\n
8. Vaccination acts upstream by preventing infection-triggered inflammation and thereby reducing acute CV events in both high-risk and healthy populations.<\/span><\/div>\n
9. For influenza vaccine: meta-analysis in ischemic heart disease\/heart failure showed ~26% relative reduction in major CV events (HR ~0.74).<\/span><\/div>\n
10. Real-world data: large English study (n\u2248193,900) aged 40-84 found 28% lower risk of first acute CV event in days 15-28 after influenza vaccination.<\/span><\/div>\n
11. Greater baseline CV risk \u2192 greater absolute vaccine benefit (e.g., early post-MI patients).<\/span><\/div>\n
12. Other vaccinations with CV associations:<\/span><\/div>\n
\u2003 a) COVID-19 full vaccination \u2192 substantially lower early CV events after SARS-CoV-2 infection.<\/div>\n
\u2003 b) Pneumococcal vaccine in elderly \u2192 ~12% reduction in CV outcomes.<\/div>\n
\u2003 c) Herpes zoster (HZ) vaccine in diabetics \u2192 HR 0.76 for major adverse CV events (MACE), HR 0.73 for coronary disease, HR 0.79 for stroke, HR 0.54 for all\u2010cause mortality.<\/div>\n
13. Mechanistic rationale: preventing infection => avoiding inflammation\/endothelial injury\/plaque destabilization\/thrombosis.<\/span><\/div>\n
14. Clinical guidelines\/consensus: e.g., European Society of Cardiology endorses vaccination as part of CV prevention for high-risk groups.<\/span><\/div>\n
15. Implementation challenges and research gaps: optimal vaccine dose (standard vs high), timing\/boosters, combination vaccines (e.g., influenza + RSV), new platforms \u2014 ongoing trials.<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

Vaccines for the Heart \u2014 How Preventing Infections Protects Against Heart Attacks and Stroke Source: From discussions and Zoom inputs during the Heart Failure & Prevention, Public Health and National Campaigns, and Heart Transplant & Advanced Heart Failure Roundtable sessions \u2014 First Regional Arab Protocols Conference (Amman, Oct 16\u201317, 2025, based on AHA -ESC preventive […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9013","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9013"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9013\/revisions"}],"predecessor-version":[{"id":9014,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9013\/revisions\/9014"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}